Skip to main content

Table 1 Clinical characteristics of batch 1 and batch 2 of case–control subjects that contributed to the blood gene-chip profiles analyzed and presented in Figs. 4 and 5

From: A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status

Gender and age-matched cohorts Age Gender (F/M) MMSE CDR-SOB
Batch 1     
ControlMCI (n = 67) 69.6 (±4.2) 41/26 (61 % F) 29.1 (±1.2) 0.07 (±0.18)
MCI (n = 39) 70.0 (±3.3) 24/15 (62 % F) 27.5 (±1.6) 1.24 (±1.60)
ControlAD (n = 64) 70.2 (±3.7) 41/23 (64 % F) 29.1 (±1.2) 0.08 (±0.18)
AD (n = 49) 69.8 (±4.4) 34/15 (69 % F) 21.8 (±4.5) 5.44 (±2.95)
Batch 2     
ControlMCI (n = 71) 70.8 (±2.9) 44/27 (62 % F) 28.9 (±1.9) 0.15 (±0.57)
MCI (n = 31) 69.5 (±4.5) 23/8 (74 % F) 27.6 (±1.9) 1.34 (±1.86)
ControlAD (n = 71) 70.8 (±2.9) 44/27 (62 % F) 28.9 (±1.9) 0.15 (±0.57)
AD (n = 40) 69.9 (±4.3) 23/17 (58 % F) 21.0 (±5.6) 5.80 (±2.75)
  1. The subjects are an age- and gender-balanced subset of the entire clinical cohort. MCI mild cognitive impairment, AD Alzheimer’s disease. Age is in years (±standard deviation). Gender is ratio of females (F) to males (M). MMSE mini-mental state examination involving a 30-point questionnaire. CDR-SOB the Washington University Clinical Dementia Rating Scale (CDR) global and Sum of Boxes (SOB) score. Application of the healthy gene ranking score provided, post hoc, similar separation of the groups with similarly robust statistical significance